Suchergebnisse - "F0P408N6V4"

PubPharm (508)

1

Multiple myeloma, haematologic malignancy and immunosuppressant and immunomodulatory medications are associated with sebaceous carcinoma, a pharmacovigilance study of the FDA adverse event reporting system

enthalten in: Journal of the European Academy of Dermatology and Venereology : JEADV | 2024

von Jedlowski, P. | DuPont, J.

2

Efficacy and safety of lenalidomide in diffuse large B-cell lymphoma : a meta-analysis of randomized controlled trials

enthalten in: Clinical and experimental medicine | 2023

von Liu, J. | Mi, R. | Chen, L. | +3

3

Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)

enthalten in: Current oncology (Toronto, Ont.) | 2023

von Lucero, J. | Al-Harbi, S. | Yee, K.

4

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma

enthalten in: Blood | 2023

von Ansari-Pour, N. | Samur, M. | Flynt, E. | +10

CommentIn: Blood. 2023 Feb 9;141(6):560-561. - PMID 36757732

5

Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma

enthalten in: Cancer cell | 2022

von Sklavenitis-Pistofidis, R. | Aranha, M. | Redd, R. | +36

CommentIn: Cancer Cell. 2022 Nov 14;40(11):1270-1272. - PMID 36379204

6

Lenalidomide bypasses CD28 co-stimulation to reinstate PD-1 immunotherapy by activating Notch signaling

enthalten in: Cell chemical biology | 2022

von Geng, C. | Chen, J. | Song, T. | +13

CommentIn: Cell Chem Biol. 2022 Aug 18;29(8):1245-1247. - PMID 35985276

7

Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCL

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2022

von Hagner, P. | Chiu, H. | Chopra, V. | +7

8

What's Old is New : The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma

enthalten in: Targeted oncology | 2022

von Costa, B. | Mouhieddine, T. | Richter, J.

9

Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1

enthalten in: Blood | 2022

von Wu, W. | Nelson, G. | Koch, R. | +25

CommentIn: Blood. 2022 Mar 31;139(13):1932-1933. - PMID 35357480

10

Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma

enthalten in: Nature communications | 2022

von Ng, Y. | Ramberger, E. | Bohl, S. | +14

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[51]